Skip to main content

Table 1 Baseline demographic and disease characteristics

From: Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis

Characteristica Total number of patients
N = 1371
Correlation coefficient P value of Pearson’s correlation coefficient with the change in mTSS
Baseline mTSS 37.9 (56.8) 0.025 0.36
Age, years 51.4 (12.0) − 0.023 0.39
Female, n (%) 1120 (81.7) 0.032 0.24
RA disease duration, years 5.9 (4.9) 0.0019 0.94
MTX dose, mg/week 15.2 (4.4) − 0.0021 0.94
SJC28 11.0 (5.1) 0.077 0.0041
TJC28 15.1 (6.3) 0.041 0.13
HAQ-DI 1.5 (0.6) 0.049 0.071
DAS28 (ESR) 6.5 (0.8) N/A 0.022
SDAI 39.9 (11.8) N/A 0.004
CDAI 38.5 (11.4) N/A 0.009
PhGA VAS, mm 61.9 (15.5) 0.054 0.048
Patient global assessment VAS, mm 61.9 (18.6) 0.041 0.13
Patient pain assessment VAS, mm 62.0 (19.5) 0.043 0.11
CRP, mg/L 13.3 (19.1) 0.057 0.033
ESR, mm/h 44.4 (20.4) 0.042 0.12
RF positive,b n (%) 1033 (75.4) 0.024 0.73
  1. CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 disease activity score by 28 joint count, ESR erythrocyte sedimentation rate, HAQ-DI health assessment questionnaire disability index, mTSS modified Total Sharp Score, MTX methotrexate, N/A not applicable, PhGA physician global assessment, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simplified Disease Activity Index, SJC28 28 swollen joint count, TJC28 28 tender joint count, VAS visual analogue scale
  2. aData are presented as mean (SD), unless indicated otherwise
  3. bRF positive indicates > 14 kIU/L for SB4, SB2, and SB5